Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6467-6474

  Li, Jie ^a   Xue, Liying ^b   Hao, Hongling ^a   Li, Ruoyu ^b   Luo, Jianmin ^b  

^a HEBEI GENERAL HOSPITAL   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Celecoxib; Chronic myelogenous leukemia; mTOR; Rapamycin

Indexed keywords

CELECOXIB; COMPLEMENTARY DNA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; K562 CELL LINE; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TREATMENT OUTCOME; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHOSPHORYLATION; PYRAZOLES; SIGNAL TRANSDUCTION; SIROLIMUS; SULFONAMIDES; TOR SERINE-THREONINE KINASES;

EID: 84905036566     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1820-5     Document Type: Article

References (47)

1. Rowley JD. Ph1-positive leukaemia, including chronic myelogenous leukaemia. Clin Haematol. 1980;9(1):55-86.
2. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36(1):93-9. (Pubitemid 14155374)
3. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science. 2001;293(5531):876-80. (Pubitemid 32743979)
4. Mancini M, Corradi V, Petta S, Martinelli G, Barbieri E, Santucci MA. mTOR inhibitor RAD001 (everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. Leuk Res. 2010;34(5):641-8.
5. Melo JV, Deininger MW. Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation. Hematol Oncol Clin North Am. 2004;18(3):545-68. (Pubitemid 38969131)
6. MohiMG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A. 2004;101(9):3130-5. (Pubitemid 38327746)
7. Parmar S, Smith J, Sassano A, Uddin S, Katsoulidis E, Majchrzak B, et al. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood. 2005;106(7):2436-43. (Pubitemid 41510818)
8. Li J, Xue L, Hao H, Han Y, Yang J, Luo J. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia. Oncol Rep. 2012;27(2):461-6.
9. Hirase C, Maeda Y, Takai S, Kanamaru A. Hypersensitivity of Phpositive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor. Leuk Res. 2009;33(3):450-9.
10. Batista A, Barata JT, Raderschall E, Sallan SE, Carlesson N, Nadler LM, et al. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol. 2011;39(4):457-72.
11. Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M, et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res. 2006;66(4):2305-13.
12. Wulff BC, Thomas-Ahner JM, Schick JS, Oberyszyn TM. Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosuppressive drugs. Int J Cancer. 2010;126(1):11-8.
13. Evans JF, Kargman SL. Cancer and cyclooxygenase-2 (COX-2) inhibition. Curr Pharm Des. 2004;10(6):627-34. (Pubitemid 38292389)
14. Li J, Hao H, Xue L, Wang C, Wang S, Wang R. Expression and significance of COX-2, bcl-2, caspase-3 in diffuse large B-cell lymphoma. J Leuk Lymphoma. 2009;18(4):223-5.
15. Li J, Xue L, Wang C, Wang R, Yang J, Hao H. Effects of celecoxib on proliferation, apoptosis and VEGF expression in NB4 cells. Cancer Res Prev Treat. 2013;40(2):147-50.
16. Subhashini J, Mahipal SV, Reddanna P. Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett. 2005;224(1):31-43. (Pubitemid 40720365)
17. Wun T, McKnight H, Tuscano JM. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res. 2004;28(2):179-90. (Pubitemid 37487998)
18. Sobolewski C, Cerella C, Dicato M, Diederich M. Cox-2 inhibitors induce early c-Myc downregulation and lead to expression of differentiation markers in leukemia cells. Cell Cycle. 2011;10(17):2978-93.
19. Zhang GS, Liu DS, DaiCW, Li RJ. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Am J Hematol. 2006;81(4):242-55.
20. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositidedependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem. 2002;277(31):27613-21. (Pubitemid 34966703)
21. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, et al. 3- Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 2004;64(4):1444-51. (Pubitemid 38235615)
22. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, et al. Using cyclooxygenase-2 inhibitors asmolecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst. 2002;94(23):1745-57. (Pubitemid 36004351)
23. Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, et al. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol. 2006;70(5):1534-41.
24. Fan X, Takahashi-Yanaga F, Morimoto S, Zhan DY, Igawa K, Tomooka K, et al. Celecoxib and 2,5-dimethyl-celecoxib prevent cardiac remodeling inhibiting Akt-mediated signal transduction in an inherited dilated cardiomyopathy mouse model. J Pharmacol Exp Ther. 2011;338(1):2-11.
25. Zhang YJ, Bao YJ, Dai Q, YangWY, Cheng P, Zhu LM, et al.mTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway. Ann Surg Oncol. 2011;18(2):580-8.
26. Vo BT, Morton Jr D, Komaragiri S, Millena AC, Leath C, Khan SA. TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology. 2013;154(5):1768-79.
27. de Oliveira AC, Candelario-Jalil E, Langbein J, Wendeburg L, Bhatia HS, Schlachetzki JC, et al. Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia. J Neuroinflammation. 2012;9:2.
28. de Oliveira AC, Candelario-Jalil E, Bhatia HS, Lieb K, Hüll M, Fiebich BL. Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2. Glia. 2008;56(8):844-55.
29. Li C, Lee PS, Sun Y, Gu X, Zhang E, Guo Y, et al. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J ExpMed. 2014;211(1):15-28.
30. Sillaber C, Mayerhofer M, Böhm A, Vales A, Gruze A, Aichberger KJ, et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest. 2008;38(1):43-52. (Pubitemid 350293855)
31. Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, et al. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. Oncol Rep. 2010;23(4):1167-72.
32. Mishra R, Miyamoto M, Yoshioka T, Ishikawa K, Matsumura Y, Shoji Y, et al. Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo. Int J Oncol. 2009;34(5):1231-40.
33. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320-4.
34. Nagai T, Ohmine K, Fujiwara S, Uesawa M, Sakurai C, Ozawa K. Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways. LeukRes. 2010;34(8):1057-63.
35. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res. 2007;13(11):3109-14. (Pubitemid 46944891)
36. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005;104(5):1045-8. (Pubitemid 41170233)
37. Bundscherer A, Vogt T, Köhl G, Landthaler M, Hafner C. Antiproliferative effects of rapamycin and celecoxib in angiosarcoma cell lines. Anticancer Res. 2010;30(10):4017-23.
38. Ross JA, Blair CK, Cerhan JR, Soler JT, Hirsch BA, Roesler MA, et al. Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1741-50.
39. Cervello M, Bachvarov D, Cusimano A, Sardina F, Azzolina A, Lampiasi N, et al. COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. OMICS. 2011;15(6):383-92.
40. Schönthal AH. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer. 2007;97(11):1465-8. (Pubitemid 350175844)
41. Wang YX, Gao JX, Wang XY, Zhang L, Liu CM. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells. Tumour Biol. 2012;33(4):957-66.
42. Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog. 1999;25(4):231-40. (Pubitemid 29372908)
43. Yao R, Rioux N, Castonguay A, You M. Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal antiinflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res. 2000;26(8):731-42. (Pubitemid 32044588)
44. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 2000;164(3 Pt 1):820-5. (Pubitemid 30637640)
45. Bundscherer A, Hafner C, Maisch T, Becker B, Landthaler M, Vogt T. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep. 2008;19(2):547-53. (Pubitemid 351176119)
46. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology. 2003;38(3):756-68. (Pubitemid 37052162)
47. Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology. 2008;135(4):1322-32.